Back HIV/AIDS HIV/AIDS Topics HIV Treatment

IAS 2015: Estrogen May Block HIV Reactivation, Hints at Gender Differences in Viral Reservoirs

Estrogen receptors on cells may play a role in HIV latency and reactivation, and drugs targeting these receptors could potentially be used to either promote reactivation of integrated viral genes or keep them silent, according to research presented at the 8th International AIDS Society Conference on HIV Pathogenesis, Treatment, and Prevention and at the preceding IAS Towards an HIV Cure Symposium last month in Vancouver.

alt

 

Read more:

IAS 2015: HIV+ Youth Are Less Likely than Adults to Achieve Viral Suppression on ART

While adolescents and young adults are about as likely as older people to be linked to care after being diagnosed with HIV, less than a third were retained in care or started antiretroviral therapy (ART), and only 7% reached undetectable viral load -- much lower than the rate for older individuals, researchers reported at the 8th International AIDS Society Conference on HIV Pathogenesis, Treatment, and Prevention last month in Vancouver. Prompt referral to youth-friendly services, however, increased the likelihood of viral suppression.alt

Read more:

IAS 2015: Altered Cholesterol Metabolism May Protect Immune Cells of Non-Progressors

Enhanced cholesterol metabolism in certain immune cells may help explain why some people with HIV can naturally control the virus with little or no disease progression, according to research presented at the 8th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention and at the preceding IAS Towards an HIV Cure Symposium last month in Vancouver. The findings suggest that regulating cellular cholesterol metabolism may offer a new approach to controlling HIV and potentially achieving a functional cure, or long-term remission.

alt

Read more:

IAS 2015: Broadly Neutralizing Antibodies Against HIV [VIDEO]

Broadly neutralizing antibodies that can recognize multiple strains of HIV may be one component of a combination strategy to achieve long-term HIV remission, experts said at a media briefing on HIV cure research at the 8th International AIDS Society Conference on HIV Pathogenesis, Treatment, and Prevention this week in Vancouver.

alt

Read more:

IAS 2015: START Supports ART For All [VIDEO]

Full results from the Strategic Timing of Antiretroviral Treatment (START) trial provide definitive evidence that starting antiretroviral therapy (ART) soon after HIV diagnosis, rather than waiting until the CD4 T-cell count falls below 500 cells/mm3, significantly reduces the risk of AIDS-related and non-AIDS illness and death, researchers reported at the 8th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention last month in Vancouver.

alt

Read more:

IAS 2015: Innovative Linkage to Care Approaches Boost Clinic Visits, HIV Treatment Uptake in African Study

A systematic effort to promote HIV testing, linkage to care for people diagnosed with HIV, and circumcision for those testing negative can result in high levels of diagnosis, linkage to care, and viral suppression in rural communities, a randomized study of combination HIV prevention conducted in South Africa and Uganda has shown. The findings were presented by Ruanne Barnabas of the University of Washington Department of Global Health at the 8th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention last month in Vancouver.

alt

Read more:

IAS 2015: WAVES Shows Elvitegravir Regimen Beats Boosted Atazanavir for Women with HIV

A study of antiretroviral treatment specifically for women with HIV showed that a single-tablet regimen containing the integrase inhibitor elvitegravir suppressed the virus better than a regimen containing ritonavir-boosted atazanavir, according to a poster presented at the 8th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention last month in Vancouver. This study is important in part because it demonstrates that including more women in clinical trials is feasible.

alt

Read more: